1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

GSK Plans Benlysta Expansion In Lupus Nephritis Based On Successful Phase III

 
• By Jessica Merrill

Benlysta was an early pioneer in systemic lupus erythematosus, but GSK now plans to expand the drug into the acute area, active lupus nephritis, with a filing in 2020.

SC1912_Lupus_1187567596_1200.jpg
GSK is expanding Benlysta in lupus • Source: Shutterstock

Nearly eight years after GlaxoSmithKline PLC's Benlysta (belimumab) became the first drug approved by the US Food and Drug Administration for lupus, the company is looking to expand the drug's indication to a substantial new subset of patients in the acute phase of the disease, even as the late-stage development space is heating up.

The company announced on 18 December positive data from a Phase III trial testing Benlysta in patients with lupus nephritis, the acute inflammation of the kidneys

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.